A Study to Evaluate APX005M in Subjects With Unresectable or Metastatic Melanoma
Status:
Recruiting
Trial end date:
2022-11-12
Target enrollment:
Participant gender:
Summary
This is a multicenter, open label, Phase 2 study, with 3 parallel cohorts. The aim of the
study is to evaluate the efficacy of APX005M administered at 2 different schedules to adult
subjects with unresectable or metastatic melanoma. Subjects who have not received prior
immunotherapy will be alternately assigned to 1 of 2 cohorts (2 different APX005M
administration schedules) as long as both are open. Subjects who have failed approved
immunotherapy regimens will be assigned to a 3rd cohort of APX005M in combination with
radiation therapy.